{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:06Z","timestamp":1787987886753,"version":"build-2784847793"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID\u201019 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT\u2010P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.<\/jats:p>","DOI":"10.1002\/ccr3.5233","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T13:21:26Z","timestamp":1642080086000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010world evidence for subcutaneous infliximab (CT\u2010P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID\u201019) pandemic: A case series"],"prefix":"10.1002","volume":"10","author":[{"given":"Sooraj","family":"Vijayan","sequence":"first","affiliation":[{"name":"Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust Wolverhampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmin","family":"Hwangbo","sequence":"additional","affiliation":[{"name":"Celltrion Healthcare Co. Ltd, Incheon Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7754-6931","authenticated-orcid":false,"given":"Nick","family":"Barkham","sequence":"additional","affiliation":[{"name":"Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust Wolverhampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102016\u2010210770"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew223"},{"key":"e_1_2_9_4_1","unstructured":"National Institute for Health and Care ExcellenceSpondyloarthritis in over 16s: diagnosis and management. 2017.https:\/\/www.nice.org.uk\/guidance\/ng65\/resources\/spondyloarthritis\u2010in\u2010over\u201016s\u2010diagnosis\u2010and\u2010management\u2010pdf\u20101837575441349.Accessed November 17 2021."},{"key":"e_1_2_9_5_1","unstructured":"European Medicines AgencyRemsima summary of product characteristics. 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/remsima\u2010epar\u2010product\u2010information_en.pdf.Accessed November 18 2021."},{"key":"e_1_2_9_6_1","unstructured":"European Medicines AgencyRemicade summary of product characteristics. 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/remicade\u2010epar\u2010product\u2010information_en.pdf.Accessed November 18 2021."},{"key":"e_1_2_9_7_1","unstructured":"European Medicines AgencyInflectra summary of product characteristics. 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/inflectra\u2010epar\u2010product\u2010information_en.pdf.Accessed November 18 2021."},{"key":"e_1_2_9_8_1","unstructured":"US Food and Drug AdministrationInflectra prescribing information. 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125544s018lbl.pdf.Accessed November 18 2021."},{"key":"e_1_2_9_9_1","unstructured":"US Food and Drug AdministrationRemicade prescribing information. 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf.Accessed November 18 2021."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1868078"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa580"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_2_9_13_1","unstructured":"Biosimilar Development.European Commission grants marketing authorisation for world's first subcutaneous formulation of infliximab Remsima SC for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis.2020.https:\/\/www.biosimilardevelopment.com\/doc\/european\u2010commission\u2010grants\u2010marketing\u2010authorisation\u2010for\u2010world\u2010s\u2010first\u2010subcutaneous\u20100001. Accessed November 17 2021."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010218705"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201017"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab174"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010219498"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217871"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010020\u201005439\u2010z"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217877"},{"key":"e_1_2_9_21_1","unstructured":"National Institute for Health and Care ExcellenceCOVID\u201019 rapid guideline: rheumatological autoimmune inflammatory and metabolic bone disorders. 2020.https:\/\/www.nice.org.uk\/guidance\/ng167\/resources\/covid19\u2010rapid\u2010guideline\u2010rheumatological\u2010autoimmune\u2010inflammatory\u2010and\u2010metabolic\u2010bone\u2010disorders\u2010pdf\u201066141905788357.Accessed November 17 2021."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20109\u20102"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010009\u20101104\u20104"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S121032"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010018\u20100306\u20101"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2021.8320\/2021"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab076.619"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(20)30392\u20107"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro\u20102020\u2010101760"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e201"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217362"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010218147"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010218171"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296\u2010021\u201004818\u20102"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/1bq5pl"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2021.8228"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102021\u2010220588"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102474\u201010\u201068"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.5233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccr3.5233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.5233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T10:26:38Z","timestamp":1693218398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.5233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/ccr3.5233"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.5233","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"value":"2050-0904","type":"print"},{"value":"2050-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e05233"}}